VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI”) has been awarded up to $350,000 CAD in grant funding by the National Research Council-Industrial Research Assistance Program (“NRC-IRAP”) to apply VBI’s eVLP Platform in the development of a respiratory syncytial virus (“RSV”) vaccine candidate. NRC-IRAP is a Canadian government-sponsored organization that provides technical and business advisory services and financial contributions to support the development and commercialization of innovative technologies developed in Canadian R&D facilities.
RSV is a respiratory virus that infects the lungs and airways and can cause serious disease in infants and older adults. According to the U.S. Centers for Disease Control, almost all children will have had an RSV infection by the time they are two years of age with 25% to 40% experiencing symptoms of pneumonia or bronchiolitis and as many as 2% requiring hospitalization.
VBI’s eVLP Platform enables the development of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the structure of enveloped viruses such as RSV. eVLPs are highly customizable, which allows VBI to rationally design vaccine candidates by carefully controlling the expression of target proteins of interest. Early data suggests that VBI’s RSV vaccine candidate may present certain RSV target proteins in an optimal shape and conformation, potentially allowing for a potent and durable immune response.
“Recent research suggests that the shape, or conformation, of the target proteins in an RSV vaccine may influence the potency and success of the candidate,” said Dr. David E. Anderson, VBI’s Senior Vice President of Research. “We are optimistic that by applying our eVLP Platform technology to RSV, we may contribute to the advancement of an improved RSV vaccine candidate. We are grateful to NRC-IRAP for their support in helping us advance this important research.”
To learn more about VBI’s RSV Vaccine Program, and the company’s collaboration with NRC-IRAP, visit: https://www.vbivaccines.com/rsv/